Back
Compare AU
Compare DRUG vs. MQAE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Healthcare Currency Hedged ETF (DRUG) and the Macquarie Core Australian Equity Active ETF (MQAE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | MQAE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 75 | 22 |
Median incremental investment | $742.79 | $1,100.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,799.88 | $2,642.78 |
Average age group | > 35 | > 35 |
Key Summary
DRUG | MQAE | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | MQAE.AX was created on 2024-05-13 by Macquarie. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to outperform the S&P/ASX 300 Accumulation Index (Index) over the medium to long term (before fees). |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) BRL - BRAZILIAN REAL (0 %) | Commonwealth Bank of Australia (9.72 %) BHP Group Ltd (9.46 %) ANZ Group Holdings Ltd (4.94 %) |
Top 3 industries | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) | Financials (57.24 %) Materials (14.95 %) Health Care (9.85 %) |
Top 3 countries | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) | Australia (95.44 %) United States (3.08 %) New Zealand (0.64 %) |
Management fee | 0.57 % | 0.03 % |
Key Summary
DRUG | MQAE | |
|---|---|---|
Issuer | BetaShares | Macquarie |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | S&P/ASX 300 Accumulation Index - AUD - Benchmark TR Net |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.03 % |
Price | $8.49 | $12.04 |
Size | $163.973 million | N/A |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.92 % | 1.25 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 14/05/2024 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | MQAE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 75 | 22 |
Median incremental investment | $742.79 | $1,100.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,799.88 | $2,642.78 |
Average age group | > 35 | > 35 |
Pros and Cons
DRUG | MQAE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | MQAE |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |